Treatment · United States
FDA approves Cobenfy, the first new mechanism for schizophrenia in seventy years
Bristol Myers Squibb's xanomeline/trospium combination acts on muscarinic receptors instead of dopamine, a structural shift in psychiatric pharmacology.
These are short summaries of research and reporting published elsewhere. We link to the original. Mental Hum does not report these stories.
Mental Hum is owned and operated by Dean Shaban
The FDA's approval of Cobenfy (xanomeline and trospium chloride) is the first time in more than seven decades that a schizophrenia medication has reached the market with a fundamentally different mechanism of action. It targets muscarinic acetylcholine receptors rather than blocking dopamine, which sidesteps a major source of the side-effect burden that has shaped antipsychotic care since the 1950s.
Clinicians and patient groups have framed the approval as the most significant moment in schizophrenia treatment in a generation, with caveats: long-term safety, access, and durability of response still need real-world data.
Read the FDA's official announcement for the indication, trial data, and labeling.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.